Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First In Class Adoptive Cell Therapies to Cure Patients Carla Biotherapeutics is a Biotech company developing first-in-class adoptive cell therapies tailored to treat diseases with high unmet medical need with a first focus on aggressive life-threatening cancer. Carla Biotherapeutics is founded by a team of seasoned clinicians, cell therapy scientists and biotech professional in Besançon, France with access to a world-class and unique cell-therapy platform. Carla Biotherapeutics’ ambition is to build and develop a pipeline of immunotherapies based on a fully integrated cell therapy platform to discover ena develop adoptive cell therapies tailored to each indication.

27 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative science to improve the health of patients To adress the unmet need to dispose of relevant tools to value the efficacy of treatments for red blood cell disorders, INNOVHEM has developed two important and unique innovations :a simple and accurate method to quantify fetal hemoglobin in each red blood cell and a specific new method to measure intravascular hemolysis. Together with several generic biological assays, INNOVHEM offers a comprehensive and innovative platform that supports the development of new treatments for red blod cell pathologies, from preclinical to phase IV evaluation.

11 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nevezyne develops its own protein expression systems and offers its expertise in the expression of recombinant proteins, for research programs, for diagnosis in animal and human health Protein Expression, Baculovirus System, Protein Purification, and Bacterial System

69 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Solution for biologics Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products. biosafety testing, Cell Banking and Storage, Viral Clearance, Potency Assay, R&D Contract, Training, …

78 similar entities Type: SMB Activities: biotech Technologies: Synthetic Biology

InBrain Pharma, a CNS disorders focused biotech, founded in 2018, exploiting through an exclusive worldwide patent license signed with the Northern France TTO, a groundbreaking therapeutic approach of advanced Parkinson’s Disease based on the research work of Pr David DEVOS and Pr Caroline MOREAU developed within their academic research Team from the Université́ de Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and the Lille University Hospital. To date, the company has raised €4.4 million in dilutive and non-dilutive financing, these funds having enabled to carry out a first phase I/IIb DIVE-I clinical trial on 12 patients, for which results …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pionnier de la thérapie régénératrice cardiaque CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans. Heart Regeneration

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low …

44 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dairy Done Differently Imagindairy, a Foodtech company, is addressing the industry bottleneck by integrating deep tech with system biology to develop a commercial and viable animal free protein-based dairy product

92 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

179 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New view for cancer therapeutics Sirius NeoSight is an innovative technological breakthrough company which aims to become a key player in the detection of subclinical neo-cancers, relapses and therapeutic monitoring of patients, thus offering doctors a new perspective on the therapeutic effectiveness implemented. Sirius NeoSight uses breakthrough patented technology from a consortium of academic laboratories with expertise in the field.

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details. Stem Cell Research, Biotechnology, and High Throughput Stemcell Research

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Xbrane is a leading science based biosimilar developer of cost effective medicines with high unmet medical need Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology. Complex generics, Protein expression, Biosimilars, Controlled release, Strain development, and Formulation

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

51 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics. Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

51 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

294 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Synsight activity is now integrated into @iktos https://iktos.ai/ https://www.linkedin.com/company/iktos/ Synsight was a company created in 2013, by two co-founders PhD Computer aided drug design: Cyril Bauvais (CEO) and Guillaume Bollot (CSO). In july 2024, Synsight was acquired by @iktos, an AI drug discovery company. Its tech is based on AI drug design and cell imaging, including a proprietary cell based assay named MTBench, to profile compounds modulators of protein-protein and protein-RNA interactions, and protein agregation. criblage virtuel, modélisation moléculaire, dynamique moléculaire, QSAR, drug design, chémoinformatique, and drug discovery

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A versatile immunotherapy for personalized cancer medicine Inovactis is developing an innovative treatment against cancer on the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. immunotherapy and personalized medicine

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building an Antibody-Drug Conjugate (ADC) Powerhouse Adcytherix is a biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADC) to treat high unmet need diseases such as cancer. The company was founded by Jack Elands and Pontifax Venture Capital with two other executives of Emergence Therapeutics, Xavier Preville and Carsten Dehning as cofounders. Adcytherix is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development. ADC and oncology

9 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics an Ipsen company is headquartered in Marseille-France. ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcells

59 similar entities Tags: FrenchTech120 FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immunotherapy against senescence StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

62 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

157 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First in class small molecules pushing cancer cells to burn out BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer

45 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creating class-leading ADCs with enhanced tumor specificity Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety. Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic …

29 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Small molecules, life-changing power. Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

130 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

3D cell shape + AI to bring the right therapies to the right patients sooner Sentinal4D is an AI-powered cancer drug discovery and development company, with close ties to the Institute of Cancer Research. Sentinal4D represents a collaboration of physics, biology and artificial intelligence to drive novel cancer therapy candidates with a high probability of clinical success. Artificial Intelligence, Computer Vision, Systems Biology, and Drug Discovery

107 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology

Next generation bioproduction platform Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical …

53 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making it possible CLEAN BIOLOGICS is a CDMO for Viral vectors, Viral vaccines and oncolytic viruses and Biosafety testing for biological products. As well as a CMO for MCB & WCB production. GMP compliance

52 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

164 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics

162 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

134 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

58 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

286 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Enabling next generation medicines. A comprehensive platform and product suite for advanced therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

6 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Making better ADCs Valink Therapeutics focusses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications. Valink is a platform therapeutics company focussing on the discovery of bsADCs based out of Cambridge, MA and London, UK. The company is a VC-backed & Y Combinator (W21)-incubated spin-out of the University of Oxford, with over $20M total capital raised.

32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

414 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

223 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

350 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Improving the safety and efficacy of gene therapies using AI Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration. Gene Control, RNA, Artificial Intelligence, Synthetic Biology, and …

42 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Advanced molecular analysis technologies to harness the power of the microbiota. To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining ADCs. Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets. Antibody Drug Conjugates, Targeted Therapy, Biotechnology, and Drug Development

26 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

151 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies.

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

175 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Boosting the body's ability to defend against the damage of aging Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Research Center & Health Development BIONOVEO offers project leaders, industrial or academic, the biological, technical and methodological skills and resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes.

103 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Industrial organ on chip technology We are developing organs on a chip that are miniature organ replicas outside human body. We are focusing on microbiome and gut on on chip that allows to develop drugs more effective and study biological processes. We are also developing easy to use instrument to run experiments on the chips.

45 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

173 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The synthetic collagen revolution NVH Medicinal world expert in synthetic collagen NVH Medicinal is a biotechnology company based in Dijon, created at the end of 2008, whose mission is based on the treatment of pathologies linked to a collagen deficiency. It develops products derived from collagen, the most abundant protein in the body and whose dysfunctions cause numerous diseases (aging, cardiovascular, inflammatory, neurological diseases, fibrosis, cancer and rare diseases). NVH's ambition is to be recognized as an innovative player in the treatment of collagen-related diseases by becoming one of the world leaders in the development, production and marketing of a …

60 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

417 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

48 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Procavea Biotech is on a mission to solve the problem of delivering RNA-based drugs to non-liver tissues. At Procavea we're developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body. Protein Engineering and RNA Delivery

43 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The cloud lab for protein designers Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bringing precision to the power of biologics with pioneering use of synthetic nanoclays for regenerative medicine. Renovos Biologics Ltd. (Renovos) is a biotech/medtech company focussed on the development of its patented synthetic nanoclay, RENOVITE®, as a drug delivery platform for regenerative medicine and beyond. Regenerative Medicine, Biomaterials, Drug Delivery, Medical Devices, Pharmaceuticals, Stem Cells, Orthopaedics, and Biotechnology

115 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Regain control with personalized muscle regeneration MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

49 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

98 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

On-target gene therapies Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Synthetic DNA production for cutting-edge biotechnology solutions. As a next-generation CDMO, NunaBio delivers universal, cell-free DNA solutions in any format, for a range of applications from therapies to advanced materials. Disposable, SaaS-controlled hardware units enable DNA production from research to commercial scale in a fraction of the space required by traditional methods. This allows researchers, developers, and manufacturers to move seamlessly from discovery to clinical development without delays, compromises, or safety risks. DNA, Custom DNA, Gene Synthesis, Synthetic Biology, Biotechnology, and DNA Synthesis

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Curileum is intervening early in serious gastrointestinal (GI) disease development with novel diagnostics & therapeutics Curileum is intervening early in serious GI disease development with novel therapeutics to detect and correct cell production in the gut mucosa Biotechnology

155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

405 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible, we are building the best-in-class mRNA design, optimisation and manufacturing platform to unlock the era of mRNA therapeutics and design-based biology.

76 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering therapies through targeted hyperoxygenation We are developing miniaturized hyperoxygenation therapies! The first application for our technology is miniaturized respiratory assist in patients suffering from lung failure.

51 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Light Activated Technologies for treating cancers and rare diseases Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.

48 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing revolutionary biomaterials for regenerative medicine. Spiderwort Inc. is a tissue engineering company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body.

45 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

88 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

CORAL BIOME PHARMA Live cultured corals for Drug discovery Coral Biome is a research and development company dedicated to the discovery of marine natural products of interest for major public health issues such as cancer, inflammation and multi-drug resistant infectious diseases. Our multidisciplinary team of research and worldwide network of collaborators gathers a unique set of competitive expertise including, aquaculture, marine biology, chemistry, cell biology and cancerology to successfully isolate marine natural products and test their biological activity. We maintain a large-scale untapped reservoir of coral species to preserve endangered species, sell corals for aquarium trade (http://www.coralbiome.com/aquaculture/) and provide research …

17 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com Immuno-oncology and Re-programming the Tumor Microenvironment

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.

34 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionising Cancer Detection Through Liquid Biopsy The Vortex VTX-1 CTC isolation platform combines high-performance engineering with clinical simplicity. Compact, automated, and easy to integrate, our solution delivers high-purity CTCs ready for downstream analysis—without the need for complex protocols or extensive training. Precision medicine starts here Circulating Tumor Cells, Cancer biomarkers, Microfluidic, Cancer research, Cancer diagnosis, Liquid biopsy, and Cancer monitoring

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers

52 similar entities Type: Startup Activities: biotech deeptech

From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology

44 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Lab-in-a-cell-devices Dynamic film about cell sensing SPAchip® technology is based on intracellular silicon microchips printed with multiple fluorescent probes to analyse and monitor cellular pathways at real time intracellular processes. The cell-based assays based on SPAchip® are compatible with High Content Screening platforms and imaging analysers. Suspended planar arrays, single cell analysis, cell signaling, flow cytometry, vaccines, and immunothepary

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Acquired by Evotec SE in July 2022, Rigenerand is now operating as Evotec (Moderna) Srl. Originating as a start-up from the University of Modena and Reggio Emilia developing and producing innovative products for pre-clinical and clinical applications of cell-based technologies for regenerative medicine and oncology, the cell technology company aims to fill therapeutic gaps for the many still incurable diseases by manufacturing smart treatments based on gene-modified cells with a specific focus on cancer With its team of leading cell therapy experts, Evotec (Moderna) adds a high-quality cGMP manufacturing site to the EVOcells platform increasing capacity, critical expertise, and capabilities …

119 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

A clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. CNS

48 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

198 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Technology to ignite the biology revolution We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists'​ ability to use synthetic biology on a scale not currently possible. Biotechnology, Synthetic Biology, DNA synthesis, Gene synthesis, and synbio

176 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We do science TETRAPHARM is a Danish biopharmaceutical company that specializes in the development of pharmaceutical drugs aimed at the central nervous system and the immune system to treat neurological diseases and mental health disorders. In addition to a strong R&D pipeline, TETRAPHARM offers a suite of tailored end-to-end CDMO services that leverages the company's proprietary drug delivery technology, ZYNDIKATE®. Neuroscience and Precision Medicine

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Machine Bio is a biotech company offering unique protein synthesis and purification solutions. Machine Bio is an early stage biotechnology company developing a novel, proprietary protein synthesis platform that can produce pure protein from a DNA template in a easy-to-use, single-step, 4 hour process. Proteins are broadly used in many industries and Machine Bio’s platform has a range of possible applications across drug discovery and development, synthetic biology research, industrial enzyme optimization, and commercial therapeutic manufacturing. Protein Synthesis, Protein Purification, Contract Protein Expression, R&D, Startup, Cell-Free Systems, and Supported Lipid Bilayer

67 similar entities Type: Startup Activities: deeptech biotech manufacturing Technologies: Synthetic Biology

Developing deuterated BEST in CLASS MET kinase Inhibitor DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2. Drug Development, Deuterated small molecules, and MET kinase inhibitor

56 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering longer, better quality lives for brain tumour patients QV Bioelectronics is a VC-backed medical device startup developing an implantable electric field therapy treatment for aggressive brain tumours.

120 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming treatment for cancer inflammation viral infection | Unveiling the Translocon to unlock innovative therapies Enodia Therapeutics, a French biotech company, is advancing first-in-class treatment for cancer, inflammatory diseases, and viral infections by targeting the translocon, a key gateway for protein secretion in the cell. Harnessing a cutting-edge AI-driven approach, we are developing selective small molecule inhibitors that block secretion and promote the degradation of pathological proteins at their source. Emerging from the Institut Pasteur and nurtured by Argobio, Enodia is built on breakthrough science with a singular mission: unveiling the translocon to unlock innovative therapies.

46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers.

55 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

357 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the power of NIK to transform the future of cancer and autoimmune disease treatment Nikaia Pharmaceuticals, an innovative company dedicated to the discovery and development of cutting-edge therapeutic solutions to improve patients' lives. 🔬💊 Our mission is to push the boundaries of science to deliver novel and effective treatments, focusing on the NIK protein (NF-κB-inducing kinase) and developing molecules capable of blocking its action.

50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology